All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your Multiple Myeloma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. Digital educational resources delivered on the Multiple Myeloma Hub are supported by an educational grant from Janssen Biotech, Inc. View funders.
Can daratumumab overcome the negative prognostic impact of high-risk cytogenetics? (II)
Bookmark this article
During the 25th Congress of the European Hematology Association (EHA), the MM Hub spoke to Luciano Costa, University of Alabama at Birmingham, Birmingham, US. We asked: Can daratumumab (dara) overcome the negative prognostic impact of high-risk cytogenetics?
Dara has impacted the lives of patients with both newly diagnosed multiple myeloma (NDMM) and relapsed/refractory disease. However, the clinical activity of dara is yet to be determined in patients with NDMM and high-risk cytogenetics.
At this year's virtual EHA Annual Congress, results will be presented from a meta analysis of patients with high-risk cytogenetics treated in trials evaluating an MM backbone treatment ± dara. Here, Luciano Costa highlights the benefit of dara observed in this setting and other key results.
Can daratumumab overcome the negative prognostic impact of high-risk cytogenetics?
Your opinion matters
1 vote - 54 days left ...
Related articles
Newsletter
Subscribe to get the best content related to multiple myeloma delivered to your inbox